Tango Therapeutics (NASDAQ:TNGX) Stock: Insider Adam Crystal Sells 5,000 Shares

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 5,000 shares of Tango Therapeutics stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $22.42, for a total transaction of $112,100.00. Following the completion of the transaction, the insider owned 115,743 shares in the company, valued at approximately $2,594,958.06. This trade represents a 4.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Adam Crystal also recently made the following trade(s):

• On Thursday, October 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $24.47, for a total value of $660,690.00.

Tango Therapeutics Stock Performance

Shares of NASDAQ:TNGX opened at $20.87 on Friday. Tango Therapeutics, Inc. has a one year low of $7.37 and a one year high of $34.39. The stock has a fifty day moving average of $23.41 and a 200-day moving average of $22.43. The company has a market capitalization of $3.52 billion, a PE ratio of -24.55 and a beta of 1.26.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05). As a group, research analysts forecast that Tango Therapeutics, Inc. will post -1.41 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on TNGX. Mizuho increased their price target on Tango Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. Guggenheim lifted their price target on Tango Therapeutics from $32.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. HC Wainwright restated a “buy” rating and set a $68.00 price objective on shares of Tango Therapeutics in a report on Thursday, October 29th. William Blair initiated coverage on shares of Tango Therapeutics in a research note on Friday, October 16th. They set an “outperform” rating for the company. Finally, Stifel Nicolaus set a $55.00 price objective on shares of Tango Therapeutics in a research note on Friday, October 23rd. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.62.

Hedge Funds Weigh In On Tango Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TNGX. TRV GP IV LLC acquired a new stake in Tango Therapeutics during the 2nd quarter worth about $120,181,383,000. Tidal Investments LLC purchased a new position in Tango Therapeutics during the 2nd quarter valued at about $1,731,000. Handelsbanken Fonder AB acquired a new position in shares of Tango Therapeutics in the 2nd quarter valued at about $9,000,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Tango Therapeutics in the 2nd quarter valued at about $19,884,000. Finally, Tema ETFs LLC purchased a new stake in shares of Tango Therapeutics in the second quarter worth approximately $1,731,000. 78.99% of the stock is currently owned by hedge funds and other institutional investors.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for cancer. The company uses functional genomics and genetic screening to identify vulnerabilities in tumor cells, including dependencies created by tumor-suppressor gene loss, and to develop targeted therapies designed to selectively attack cancer cells.

Tango’s pipeline includes small-molecule programs for genetically defined solid tumors. Its lead program, TNG462, is an MTA-cooperative PRMT5 inhibitor being developed for cancers with MTAP gene deletions.